Rabies vaccine study seeks to sharpen prevention strategies
NCT ID NCT07399951
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed early-phase study looked at how healthy adults respond to the rabies vaccine when given alone or with an immune-boosting shot (rabies immune globulin). Thirty participants received different combinations of vaccine and immune globulin to compare antibody levels over time. The goal is to better understand how pre-existing antibodies affect vaccine response, which could lead to more effective rabies prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rabies vaccine (Imovax or RabAvert) and rabies immune globulin (HyperRAB)
What this could lead to
If successful, this study could help refine rabies vaccination schedules, potentially reducing doses or improving protection.
What could go wrong
This is a small, early-phase study in healthy people, not patients. Results may not apply to real-world rabies exposure or different populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine Infectious Disease Clinical Trials Unit.
St Louis, Missouri, 63110, United States